Investor Insights from CEOs & CFOs | Financial Results & Presentations | seat11a

Wacker Chemie AG FY 2024: Key Takeaways

Wacker Chemie FY24 Financial Results: Strong Performance & Future Strategy

Exclusive Financial Analysis by Jörg Hoffmann

In this exclusive presentation, Jörg Hoffmann, Head of Investor Relations at Wacker Chemie, analyses the company’s FY24 financial results in-depth, discussing key achievements, challenges, and future outlook.

Financial Performance & Key Metrics

Wacker Chemie demonstrated remarkable resilience in a challenging economic environment, delivering solid financial results in FY24. The report highlights:

- Revenue & Earnings: A detailed breakdown of sales growth, profitability, and margin performance across core business divisions.

- Operational Efficiency: Efforts to enhance production efficiency and cost-control strategies that contributed to financial stability.

- Market Positioning: Strength in the chemical and polymer markets, backed by innovation and sustainability initiatives.

Industry Challenges & Macroeconomic Factors

Wacker Chemie has navigated significant industry challenges, including:

- The impact of inflationary pressures, raw material costs, and energy prices on operations.

- The effects of geopolitical uncertainties and global supply chain disruptions.

- Strategies implemented to mitigate risks and ensure long-term growth.

Strategic Initiatives & Future Growth Prospects

Wacker Chemie’s unwavering commitment to sustainability and innovation remains a cornerstone of its operations. The company continues to focus on developing environmentally friendly chemical solutions and advanced material technologies, ensuring that business practices align with ethical values.

- Expansion Plans: Investments in new production facilities and market expansion strategies for 2025 and beyond.

- Dividend Policy & Shareholder Value: Insights into capital allocation and returns for investors.

Conclusion

Jörg Hoffmann presents a comprehensive overview of Wacker Chemie’s robust financial performance in FY24. He outlines a positive outlook for 2025, emphasizing the company’s commitment to innovation, sustainability, and shareholder value. With continued strategic growth initiatives, Wacker Chemie aims to enhance profitability and maintain its market leadership in the chemical industry.

▶️ Other videos:Elevator Pitch: ⁠https://seat11a.com/investor-relations-elevator-pitch/⁠Company Presentation: ⁠https://seat11a.com/investor-relations-company-presentation/⁠Deep Dive Presentation: ⁠https://seat11a.com/investor-relations-deep-dive/⁠Financial Results Presentation: ⁠https://seat11a.com/investor-relations-financial-results/⁠ESG Presentation: ⁠https://seat11a.com/investor-relations-esg/⁠

📲 Follow seat11a:

🔗 Website: https://seat11a.com

📢 LinkedIn: https://www.linkedin.com/company/seat11a

🐦 Twitter: https://x.com/seat11a_com

🎧 Spotify: https://open.spotify.com/show/1XXbzcQmY3fbeeoodYIO0H

T&CThis publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on ⁠www.seat11a.com/legal⁠ and ⁠www.seat11a.com/imprint⁠.

Hypoport SE's 2024 Financial Performance & Strategic Outlook with CEO Roland Slabke

In this exclusive financial update, Hypoport SE CEO Roland Slabke presents the company's preliminary 2024 financial results, offering key insights into the firm's performance over the past year and its strategy for the future. Hypoport, a leading fintech company specializing in digital financial services, housing finance, and insurance platforms, has navigated market challenges while reinforcing its position as an essential player in Germany's financial ecosystem.

Strong Market Position & Business Growth

Roland Slabke highlights Hypoport's role as an industry leader in Germany's mortgage and financial services market. Despite a fluctuating economic landscape, the company has maintained stable revenue streams and expanded its client base across digital platforms. With continuous investment in technological innovation, Hypoport has further strengthened its B2B financial solutions for banks, insurers, and real estate markets.

Key Financial Metrics & Performance Indicators

The 2024 fiscal year was shaped by macroeconomic trends, interest rate developments, and changing consumer behaviour. Hypoport has reported resilient revenue figures despite these challenges, demonstrating its adaptability and stability in shifting market conditions. The company's focus on efficiency, cost management, and long-term value creation ensures sustainable profitability, reassuring our stakeholders.

Market Challenges & Response Strategy

With ongoing volatility in the European real estate and mortgage sectors, Hypoport has implemented strategies to mitigate risks while capitalizing on emerging opportunities in digital lending and financial advisory services. Slabke discusses how the company's scalable technology-driven platforms provide robust solutions amid rising regulatory demands and evolving customer expectations.

Future Growth & Strategic Priorities

Looking ahead to 2025, Hypoport remains committed to enhancing digital transformation, broadening its market reach, and strengthening its core business segments. With a strong focus on technological innovation, AI-driven financial solutions, and expanding partnerships, Hypoport aims to drive continued growth, profitability, and investor confidence.

Conclusion

As Hypoport SE continues to solidify its presence in Germany's digital finance sector, CEO Roland Slabke's presentation underscores the company's resilience, strategic foresight, and commitment to long-term success. This strategic foresight instils confidence in investors and industry stakeholders, who will closely watch Hypoport's next moves as it shapes the future of digital financial services, lending, and real estate financing in Germany and beyond.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Palfinger AG Records Second-Best Financial Year in 2024 – CFO Presents Key Insights and 2025 Growth Outlook

Exceptional Financial Performance in 2024

Palfinger AG, a global leader in innovative lifting solutions, has announced its second-best financial year in company history, reinforcing its strong position in the market. The company's CFO presents a deep dive into the 2024 financial performance, key drivers behind the record-setting results, and an optimistic outlook for 2025.

A Year of Resilient Growth and Strategic Expansion

Palfinger AG navigated the challenges of a volatile economic environment with exceptional financial performance in 2024. The CFO highlights:

Strong revenue growth driven by demand across construction, logistics, and industrial sectors.

Increased EBIT and profitability, reflecting operational efficiency and smart cost management.

Expansion into new markets and technological innovation, strengthening its global footprint.

Continued investment in sustainability, reinforcing the company's long-term ESG commitments.

What Drove the Record-Breaking Financial Results?

The success of 2024 can be attributed to:

Diversification of product offerings to meet evolving industry needs.

Optimization of production processes, leading to increased efficiency.

Resilience in supply chain management, mitigating global disruptions.

Strong order intake across various business segments.

The CFO emphasizes that these factors have not only contributed to financial success but also positioned Palfinger AG for sustainable future growth.

Positive Outlook for 2025: What Investors Can Expect

Looking ahead to 2025, Palfinger AG is optimistic about continued growth and market leadership. The CFO outlines the company's strategic priorities, including:

Further expansion into international markets to strengthen revenue streams.

Investments in digitalization and automation, enhancing efficiency and innovation.

Sustainable and eco-friendly solutions aligning with global ESG standards.

Increased focus on customer-centric solutions to drive demand and satisfaction.

Despite global economic uncertainties, Palfinger AG remains steadfast in its confidence in maintaining strong profitability and operational excellence.

Investor Confidence and Market Performance

Palfinger AG's stock performance reflects investor confidence in the company's long-term growth strategy. Analysts acknowledge the company's impressive financial trajectory, highlighting the following:

Strong earnings and profitability despite market fluctuations.

Commitment to innovation and technology, ensuring competitive advantage.

Consistent dividends and shareholder returns making Palfinger a reliable investment.

Conclusion: A Bright Future for Palfinger AG

With record-setting financial performance in 2024 and a strong strategic plan for 2025, Palfinger AG is poised for continued success. The CFO's presentation underscores the company's commitment to operational excellence, financial stability, and long-term growth, making it a compelling investment opportunity for stakeholders.

Stay tuned for more insights as Palfinger AG continues to set new industry benchmarks and drive innovation in lifting solutions.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is intended solely for informational purposes and does not constitute investment advice. By using this website, you agree to our terms and conditions as outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Introduction to Wacker Chemie

:Joerg Hoffmann introduces Wacker Chemie, a global leader in speciality chemical manufacturing. With over 16,000 employees, the company achieved an impressive €6.4 billion in sales and €824 million EBITDA in 2023, a testament to its exceptional performance. The company operates through four distinct business segments, each vitally involved in delivering innovative solutions to diverse industries worldwide. These segments are Silicones, Polymers, Polysilicon, and solutions.

Business Segments at a Glance

Silicones

Wacker'sThe largest segment, Silicones, represents a cornerstone of Wacker’s business. Silicones are versatile materials in countless applications, from construction and healthcare to renewable energy and automotive. With 85% of sales driven by speciality silicone products, the segment demonstrates WaWacker'socus on high-margin, customised solutions. The presentation also highlights the integration of silicones with polysilicon production, maximising resource efficiency.

Polymers

The Polymers segment specialises in adhesives, paints, and coatings, playing a key role in sustainable construction. Through innovations like dispersible polymer powders and vinyl acetate ethylene-based adhesives, Wacker delivers solutions that enhance energy efficiency and reduce carbon footprints. Applications include construction materials, food packaging, and textiles, with significant growth driven by the global trend toward urbanisation and green building standards.

Polysilicon

worldwideWacker is the global leader in polysilicon manufacturing for semiconductor and solar applications. Nearly half of all computer microchips globally contain Wacker polysilicon, which is pivotal in enabling cutting-edge technologies such as artificial intelligence, connectivity, and renewable energy solutions. The solar segment also benefits from WaWacker'superior quality and cost efficiency, which positions the company as a leader in sustainable energy transformation.

Biosolutions

The Biosolutions division is a fast-growing business focusing on biotechnology and advanced medicine. Through mRNA and pDNA production innovations, Wacker addresses high-growth markets in biopharmaceuticals and nutraceuticals. Its expertise in microbial fermentation supports next-generation pharmaceuticals, emphasising sustainability and scalability in drug manufacturing processes.

Strategic Focus and Market Leadership

Wacker Chemie prides itself on being a market leader in all its segments, ranking as #1 or #2 globally. The presentation underscores the company’s unique position in leveraging its integrated value chain and advanced technology to provide tailored solutions across multiple industries, including construction, healthcare, electronics, and renewable energy. WaWacker'sommitment to innovation is evident in its continuous development of new products and solutions.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

BRAIN Biotech Group, a leading player in industrial biotechnology, has released its 3M FY 24/25 financial results, highlighting robust double-digit sales growth in its BRAIN Biocatalysts division. CFO Michael Schneiders provides an in-depth breakdown of the company’s performance, innovation-driven strategies, and long-term financial outlook.

• The BRAIN Biocatalysts division achieved double-digit growth, reinforcing its position as a leader in customized enzyme development.
• The company continues to expand its biotech solutions across industries, driving revenue through innovative, sustainable applications.

• Strong operational performance contributed to healthy margins, reflecting the company’s ability to monetize its proprietary technologies.
• Increased investment in R&D and strategic partnerships supports long-term scalability and profitability.

• BRAIN Biotech continues to expand its global footprint, offering bio-based solutions to industries ranging from food & nutrition to agriculture and biopharma.
• Its highly specialized enzymes and biocatalysts drive efficiency and sustainability in key sectors.

The core BRAIN Biocatalysts division has been the primary growth engine, leveraging advanced enzyme technologies to create cutting-edge biotechnological solutions for industrial applications. The division’s success underscores the company’s ability to meet increasing market demand for high-performance, sustainable solutions.

BRAIN Biotech has made significant R&D investments, fostering new product development and enhancing the application range of its proprietary biocatalysts and microbial platforms. These innovations strengthen the company’s competitive edge, ensuring it remains at the forefront of biotechnology advancements.

Environmental responsibility is not just a part of BRAIN Biotech’s mission, it’s at the core. The company integrates sustainable practices across its entire value chain, providing bio-based alternatives to reduce waste, improve efficiency, and enhance eco-friendly production. This approach aligns with global sustainability goals and increases the company’s attractiveness to investors and business partners, reassuring them of our ethical values and long-term viability.

CFO Michael Schneiders emphasizes that BRAIN Biotech’s financial success is driven by a long-term strategic vision focused on:

• ✔ Sustainable revenue growth through continued expansion of its biotech platforms.
• ✔ Enhanced operational efficiency via process optimization and technological advancements.
• ✔ Investment in next-generation biotech solutions to drive long-term profitability.

The company is well-positioned to capitalize on the growing demand for industrial biotech applications. With a robust pipeline of innovations and a solid financial base, BRAIN Biotech Group remains committed to delivering value for its customers and shareholders. This commitment should make our stakeholders feel secure about their investment in our company.

BRAIN Biotech’s 3M FY 24/25 financial results showcase a company on the rise, driven by innovation, sustainability, and a clear strategic focus. CFO Michael Schneiders’ insights underline the company’s strong growth trajectory and commitment to long-term success. Investors and industry stakeholders can expect continued expansion, breakthrough biotechnological solutions, and increasing market influence as the company pushes forward in the evolving biotech landscape.

T&CThis publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

PSI Software SE: Driving Digital Transformation in Process Optimization

In this in-depth presentation, Karsten Pierschke, Head of Investor Relations & Corporate Communications at PSI Software SE, provides an insightful overview of PSI’s business model, strategic direction, and financial outlook. As a technology leader in process control software, PSI has been at the forefront of industrial digital transformation for over 55 years.

1969 – PSI Software SE established itself as a leading software provider for process control and optimization systems in various vertical markets.

The company specializes in:
– Energy infrastructure
– Metals production
– Discrete manufacturing
– Logistics
– Industrial AI

Serving a niche B2B market, PSI tailors solutions to specific industry challenges.

With over 2,300 employees across 17 international locations, PSI remains committed to technological innovation and customer-centric solutions. The company generated €270 million in revenue in 2023, focusing on AI-driven, cloud-based transformation.

PSI Software SE is structured into four key vertical markets:
– A European leader in energy control systems, PSI provides smart grid solutions for electricity, gas, oil, district heating, and water utilities.
– PSI’s globally leading Manufacturing Execution System (MES) and AI-driven supply chain optimization support decarbonization and energy efficiency in metals production and process industries.
– The company delivers ERP and MES solutions for the automotive and mechanical engineering industries, optimizing production efficiency and resource management.
– PSI’s logistics software suite covers warehouse management, transport management, and supply chain optimization, ensuring efficient and automated workflows.

PSI is divesting its Mobility business unit to streamline its core focus areas.

PSI operates in 17 countries and serves a highly selective customer base of around 1,700 businesses:
– Energy grid operators such as E.ON and international network providers
– Metals industry giants like Nippon Steel, Nucor, and US Steel
– Automotive OEMs and suppliers in Germany, Europe, and North America
– Retail and logistics companies in Eastern Europe and Asia-Pacific

Challenges and Resilience
PSI Software SE faced several operational and external challenges in recent years, impacting profitability:
– 2022: Withdrawal from Russian operations due to geopolitical tensions led to a revenue decline
– 2023: Operational issues in energy grid projects affected EBIT margins, resulting in a lower-than-expected 2% margin
– 2024: A cyberattack in February disrupted business for several months, delaying revenue recognition into 2025

Despite these challenges, PSI has demonstrated remarkable resilience, retaining all its customers and maintaining a strong order backlog. This positions the company for significant growth in 2025, a testament to its stability and potential.

▶️ Other videos:
Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C
This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

eDreams ODIGEO's 9M 2025 Key Takeaways

Q3 FY25 Financial Results: eDreams ODIGEO’s Record Performance

In-Depth Analysis by CFO Avid Elízaga

In the latest Q3 FY25 financial results presentation, eDreams ODIGEO’s CFO, Avid Elízaga, provides an in-depth analysis of the company’s strong performance, driven by its Prime subscription model. This model, which offers exclusive benefits to subscribers, has been a key driver of our record-breaking profitability. The company has achieved a cash margin surge and a 70% year-over-year increase in quarterly profit, largely due to the increasing maturity of our Prime subscribers.

Key Financial Highlights

Prime Membership Growth

Prime subscribers grew 26% YoY, surpassing 7 million members.

They are on track to meet the self-imposed target of 7.25 million members by the end of FY25.

Profitability & Revenue Expansion

Cash margin surged by 40% YoY, driven by increasing Prime subscriber maturity.

Prime cash revenue margin grew 19%, while cash EBITDA increased 52%.

Non-Prime revenue showed a smaller-than-expected decline, with a 10% revenue margin increase in Q3.

Free Cash Flow & Shareholder Value

€124 million free cash flow generated in the first nine months, up 91% from the prior year.

The company repurchased €40 million in shares, reinforcing confidence in its undervalued stock.

Plans for further share buybacks as part of the company’s capital allocation strategy.

Strategic Insights & Future Outlook

eDreams ODIGEO is positioned for continued growth with three key targets for FY26:

- Adding 1 million+ new Prime members,

- Achieving cash EBITDA between €215-220 million,

- Generating over €120 million in free cash flow ex non-Prime working capital.

The company remains optimistic despite industry challenges, emphasizing its ability to navigate economic fluctuations, inflation, and travel disruptions. eDreams’ inspiring long-term vision includes expanding Prime’s market penetration, enhancing customer experience, and maintaining industry leadership in the subscription-based travel model.

Conclusion

With Prime now contributing 83% of total cash marginal profit, eDreams ODIGEO has proven the sustainability of its business model. The company’s unwavering commitment to delivering exceptional financial results, outperforming industry trends and unlocking substantial shareholder value, provides investors with a sense of security. They can expect strong profitability, robust subscriber growth, and an expanding free cash flow trajectory as eDreams advances towards its FY25 and long-term financial targets.

This presentation reaffirms eDreams ODIGEO’s competitive advantage, setting the stage for further innovation, growth, and financial success in the evolving travel industry.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

In this in-depth presentation Thu Anh, an expert from the investor relations team at Carl Zeiss Meditec AG, offers an exhaustive exploration of the company’s innovative approach towards cataract treatment, a critical offering in their ophthalmology portfolio.

Beginning with an introduction to cataracts, a common eye condition predominantly affecting individuals over 50, Thu Anh elaborates on how this ailment, caused by ageing, leads to the clouding of the eye’s crystalline lens, progressively impairing vision. She explains that the only effective solution to this issue is to replace the clouded lens with a clear intraocular lens (IOL). This procedure is undertaken more than 25 million times globally each year.

Thu Anh offers a detailed breakdown of the modern cataract treatment procedure. She explains how the process initiates with a main incision at the juncture between the cornea and sclera, followed by the careful extraction of the cloudy lens using ultrasound and suction. Subsequently, an artificial IOL is gently implanted into the clear capsular bag, restoring clear vision for the patient.

The key focus of this presentation is the unveiling of Carl Zeiss Meditec’s ground-breaking ‘Cataract Workflow’. This systematized, four-step process enhances clinical efficiency and improves patient outcomes. The steps encompass the assessment and education of the patient, planning pre-operative measures, conducting the surgical procedure, and carrying out follow-up processes.

Multiple crucial components of this workflow are underscored. The IOL Master 700 is showcased as an exceptional diagnostic tool offering precise biometric measurements, thereby minimizing the chances of refractive surprises after surgery. The EQ Workplace is another significant asset, functioning as a data management hub that streamlines the clinical workflow by providing access to data at any time, from any place. It also aids in surgical planning, IOL calculation, and ordering. Finally, the Quatera 700, Zeiss’s first phacoemulsification machine, serves as a centralized surgical platform that improves the effectiveness and efficiency of the surgical procedure.

Towards the conclusion, Thu Anh shares testimonials from surgeons who have adopted this workflow and digitalization, experiencing enhanced system efficiency, reduced dependency on manual resources, and minimized transcription errors. The video wraps up with a promising outlook for the future, where Carl Zeiss Meditec seeks to standardize its cataract workflow as the primary treatment for cataract patients. The company also envisions a continued leader in the digitalization of the ophthalmic industry, projecting robust growth in this significant market segment of ophthalmology.

=================================

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

=================================

T&C

This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Sebastian Frericks, Head of Investor Relations atCarl Zeiss Meditec AG, presents theQ1 2024/25 financial results and discusses revenue growth, market challenges, and future strategies.

At the start of the fiscal year,Carl Zeiss Meditec recorded a 3% revenue growth, primarily driven by theDOCTER OPTICS (DO) acquisition. However, underlyingorganic momentum remained negative, as anticipated. The company had previouslyguided for this decline in December, signalling a temporary headwind due to specific market conditions.

Despite anegative investment climate in China, with hospitals delaying purchases while awaiting stimulus measures, Carl Zeiss Meditec has shown resilience. Last year's strong post-pandemic delivery phase also meant that this quarter faced a challenging comparison base, but the company has navigated these challenges with determination.

Another key issue was theprice decline in intraocular lenses (IOLs) due to China'sVolume-Based Procurement (VBP) regulations, impacting pricing power in this segment. Despite these headwinds, thecompany's order backlog grew by nearly €100 million, reaching€382 million in Q1, signalling stronger demand for future quarters.

Notably, the company reported itsfirst consistent order turnaround in 12–18 months, boosting confidence that organic performancehas bottomed out and is set for an upturn.

Due to theweak organic performance and product mix effects, particularly lower sales ofhigh-margin surgical microscopes, Carl Zeiss Meditec'sEBITDA declined at the start of the fiscal year. However, theophthalmology division grew by 7%, primarily driven by theDO acquisition. This strategic growth, despite the decline, demonstrates thecompany's forward-thinking approach.

Similarly, themicrosurgery division faceda 7.8% organic decline, mainly because of tough comparisons against a strong prior-year period driven by backlog clearance. However, the company is ramping up sales for the next-genKINEVO neurosurgical microscope, expected todrive recovery in the coming quarters.

One of thebiggest developments in Q1 2024/25 was theearly approval of VISUMAX 800 in China. Thislatest-generation femtosecond laser system revolutionizes laser vision correction by enabling alenticular cut in 6–8 seconds, significantly enhancingsafety, automation, and patient comfort.

Carl Zeiss Meditecmaintains a conservative full-year outlook, citinggeopolitical risks and macroeconomic uncertainties in China. However, stabilization signs insurgical procedure volumes suggest the marketmay have reached its lowest point.

Key growth drivers moving forward:

✅Stronger order backlog supporting future revenue momentum

✅VISUMAX 800 launch in China & US driving market expansion

✅KINEVO 900S rollout in neurosurgery boosting high-margin sales

✅Potential public stimulus measures in China as a wildcard for upside

From amid-term perspective (3–5 years), Carl Zeiss Meditec aims forEBITDA margin recovery to 16–20%, depending onmarket recovery and product adoption.

Carl Zeiss Meditec'sQ1 2024/25 results highlight atransitional phase—whileshort-term challenges persist, strategic investments in innovation and operational efficiency position the company forstronger performance ahead.

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

CEO Presentation: Carl Zeiss Meditec AG Q1 2024/25 Financial Performance

In this comprehensive presentation, the CEO of Carl Zeiss Meditec AG delves into the company's performance during the first quarter of the 2024/25 fiscal year, highlighting a modest increase in revenue. The discussion begins with an overview of the financial results, where the CEO reports a slight revenue growth compared to the same period in the previous year. This growth is attributed to steady demand across key product lines and strategic market expansions.

The CEO emphasizes the performance of the Ophthalmic Devices segment, which experienced a notable uptick in sales. This success is largely due to the strong market acceptance of their innovative surgical and diagnostic products. The company's commitment to advancing ophthalmic technology has reinforced its position as a leader in this sector.

Despite challenges, the Microsurgery segment demonstrated resilience. The CEO acknowledges a slight revenue decline, attributing it to temporary market fluctuations. However, he anticipates a rebound in the upcoming quarters. The company's efforts to strengthen this segment through targeted marketing strategies and introducing new products designed to meet evolving customer needs are a testament to its resilience and commitment to growth.

The presentation also covers the company's regional performance. The Asia-Pacific region emerged as a significant contributor to revenue growth, driven by increased demand in countries such as China and India. The company maintained stable performance in the Americas and EMEA regions, with ongoing initiatives to capture additional market share.

Innovation remains a cornerstone of Carl Zeiss Meditec's strategy. The CEO discusses recent investments in research and development, focusing on cutting-edge technologies that enhance diagnostic accuracy and surgical outcomes. These innovations are expected to drive future growth and provide a competitive edge in the medical technology landscape.

Underlining its commitment to sustainability and corporate responsibility, the company is actively reducing its environmental footprint through energy-efficient manufacturing processes and sustainable product designs. Initiatives promoting diversity and inclusion within the workforce are also underway, fostering a culture that values varied perspectives and experiences. These efforts are a source of pride for the company and its stakeholders.

Looking ahead, the CEO outlines the strategic priorities for the remainder of the fiscal year. Key focus areas include expanding the global sales network, accelerating digital transformation efforts, and exploring strategic partnerships to enhance the product portfolio. Despite potential macroeconomic headwinds, the company remains cautiously optimistic about achieving its financial targets.

In conclusion, the CEO reiterates Carl Zeiss Meditec's unwavering dedication to delivering value to its stakeholders—shareholders, customers, and patients. By leveraging innovation, operational excellence, and a customer-centric approach, the company aims to successfully navigate the dynamic healthcare environment, always keeping the best interests of its stakeholders at heart

▶️ Other videos:

Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/

Company Presentation: https://seat11a.com/investor-relations-company-presentation/

Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/

Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/

ESG Presentation: https://seat11a.com/investor-relations-esg/

T&C

This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.